

## References

1. Lushchak, V.I., *Free radicals, reactive oxygen species, oxidative stress and its classification*. Chemico-biological interactions, 2014. **224**: p. 164-175.
2. Commoner, B., J. Townsend, and G.E. Pake, *Free radicals in biological materials*. Nature, 1954. **174**(4432): p. 689.
3. Weidinger, A. and A.V. Kozlov, *Biological activities of reactive oxygen and nitrogen species: oxidative stress versus signal transduction*. Biomolecules, 2015. **5**(2): p. 472-484.
4. Pisoschi, A.M. and A. Pop, *The role of antioxidants in the chemistry of oxidative stress: a review*. European journal of medicinal chemistry, 2015. **97**: p. 55-74.
5. Davies, M.J., *Protein oxidation and peroxidation*. Biochemical Journal, 2016. **473**(7): p. 805-825.
6. Deavall, D.G., et al., *Drug-induced oxidative stress and toxicity*. Journal of toxicology, 2012. (2012): Article ID 64546, 13 pages.
7. Sentellas, S., et al., *GSSG/GSH ratios in cryopreserved rat and human hepatocytes as a biomarker for drug induced oxidative stress*. Toxicology in Vitro, 2014. **28**(5): p. 1006-1015.
8. Pandey, K.B. and S.I. Rizvi, *Redox biology of aging: focus on novel biomarkers*, in *Free Radicals in Human Health and Disease*, Springer. **2015**: p. 279-290.
9. Valko, M., et al., *Redox-and non-redox-metal-induced formation of free radicals and their role in human disease*. Archives of toxicology, 2016. **90**(1): p. 1-37.
10. Sies, H., *On the History of Oxidative Stress: Concept and Some Aspects of Current Development*. Current Opinion in Toxicology, 2018. **7**: p. 122-126
11. Erođlu, O., et al., *The Protective Effect of Cortixin on Cisplatin-Induced Ototoxicity*. The journal of international advanced otology, 2018. **14**(1): p. 27-33.
12. Bobylev, I., et al., *Depletion of mitofusin-2 causes mitochondrial damage in cisplatin-induced neuropathy*. Molecular neurobiology, 2018. **55**(2): p. 1227-1235.
13. Kalra, P., et al., *Terminalia chebula supplementation attenuates cisplatin-induced nephrotoxicity in Wistar rats through modulation of apoptotic pathway*. Natural Product Research, 2018. (2018): p. 1-5.
14. Hasanvand, A., et al., *Ameliorative effect of ferulic acid on gentamicin-induced nephrotoxicity in a rat model; role of antioxidant effects*. Journal of Renal Injury Prevention, 2018. **7**(2): p. 73-77.
15. Wu, Q., et al., *Mechanism of cyclosporine A nephrotoxicity: Oxidative stress, autophagy, and signalings*. Food and Chemical Toxicology, 2018. **118**: p. 889-907.
16. Gorini, S., et al., *Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib*. Oxidative medicine and cellular longevity, 2018. **2018** Article ID 7582730, 15 pages.
17. Javed, S., W. Ahsan, and K. Kohli, *Pharmacological influences of natural products as bioenhancers of silymarin against carbon tetrachloride-induced hepatotoxicity in rats*. Clinical Phytoscience, 2018. **4**(1): p. 18.
18. Sharma, S. and P. Vijaya, *Cardioprotective Effects of Lycopene against Cadmium Induced Toxicity in Albino Mice*. International Journal of Health Sciences and Research (IJHSR), 2015. **5**(8): p. 507-513.
19. Nimse, S.B. and D. Pal, *Free radicals, natural antioxidants, and their reaction mechanisms*. Rsc Advances, 2015. **5**(35): p. 27986-28006.

20. Mukeshwar, P., et al., *Phytomedicine: An ancient approach turning into future potential source of therapeutics*. Journal of Pharmacognosy and phytotherapy, 2011. **3**(2): p. 27-37.
21. Jaradat, N.A., et al., *Herbal remedies use by breast cancer patients in the West Bank of Palestine*. Journal of ethnopharmacology, 2016. **178**: p. 1-8.
22. Organization, W.H., *WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems*. 2004.
23. Ekor, M., *The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety*. Frontiers in pharmacology, 2014. **4**: p. 177.
24. Kinsella, J., et al., *Possible mechanisms for the protective role of antioxidants in wine and plant foods*. Food technology, 1993. **47**: p. 85-89.
25. LAL, U., et al., *HPLC analysis and standardization of Arjunarishta—an Ayurvedic Cardioprotective formulation*. Scientia Pharmaceutica, 2009. **77**(3): p. 605-616.
26. Devaraj, V., et al., *Hepatoprotective activity of Hepax-A polyherbal formulation*. Asian Pacific journal of tropical biomedicine, 2011. **1**(2): p. 142.
27. Lal, J., *Turmeric, curcumin and our life: a review*. Bull Environ Pharmacol Life Sci, 2012. **1**(7): p. 11-17.
28. Govind, P., *Some important anticancer herbs: a review*. International Research Journal of Pharamacy, 2011. **2**: p. 45-53.
29. Sharma, R., T. Raghuram, and N.S. Rao, *Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes*. European Journal of Clinical Nutrition, 1990. **44**(4): p. 301-306.
30. Leatherdale, B., et al., *Improvement in glucose tolerance due to Momordica charantia (karela)*. Br Med J (Clin Res Ed), 1981. **282**(6279): p. 1823-1824.
31. Waltenberger, B., et al., *Novel Natural Products for Healthy Ageing from the Mediterranean Diet and Food Plants of Other Global Sources—The MediHealth Project*. Molecules, 2018. **23**(5): p. 1097.
32. Sekhar, S., et al., *In vitro antioxidant activity, lipoxygenase, cyclooxygenase-2 inhibition and DNA protection properties of Memecylon species*. International Journal of Pharmacy and Pharmaceutical Sciences, 2013. **5**(Suppl.): p. 257-262.
33. Nair, N. and A.N. Henry, *Flora of Tamil Nadu, India*. 1983. Ser 1, Vol I, Botanical survey of India, Coimbatore.
34. Elavazhagan, T. and K.D. Arunachalam, *PHYTOCHEMICAL AND ANTIBACTERIAL. Extraction*, 2010. **2**(4): p. 498-503.
35. Nualkaew, S., et al., *Anti-inflammatory, analgesic and wound healing activities of the leaves of Memecylon edule Roxb*. Journal of ethnopharmacology, 2009. **121**(2): p. 278-281.
36. Naidu, V., et al., *Apoptogenic activity of ethyl acetate extract of leaves of Memecylon edule on human gastric carcinoma cells via mitochondrial dependent pathway*. Asian Pacific journal of tropical medicine, 2013. **6**(5): p. 337-345.
37. Hullatti, K.K. and V.R. Rai, *Antimicrobial activity of Memecylon malabaricum leaves*. Fitoterapia, 2004. **75**(3-4): p. 409-411.
38. Ramaiah, M., B.G. Rao, and G. Chakravarthi, *Antidiabetic Activity O f Methanolic Extract Of Memecylon Malabaricum Cogn(Melastomataceae) Leaves*. International Journal Of Pharma And Bio Sciences, 2013. **4**: p. 822-828.

39. Dhanabal, S.P., et al., *Antipsoriatic activity of extracts and fractions obtained from Memecylon malabaricum leaves*. Journal of Pharmacy and Pharmacology, 2012. **64**(10): p. 1501-1509.
40. Bhandary, M. and K. Chandrashekar, *Herbal therapy for herpes in the ethno-medicine of Coastal Karnataka*. 2011. **10**(3): p.528-532.
41. Yashoda, K., et al., *Antimicrobial and Radical Scavenging Activity of Memecylon malabaricum Memecylon talboltianum Brandis*. Science, Technology and Arts Research Journal, 2014. **3**(2): p. 174-179.
42. Killedar, S.G., et al., *Phytochemical screening and in vitro antioxidant potential of Memecylon umbellatum Burm leaf extracts*. Journal of Drug Delivery and Therapeutics, 2014. **4**(2): p. 30-35.
43. Murugesan, S., A. Pannerselvam, and A.C. Tangavelou, *Phytochemical screening and Antimicrobial activity of the leaves of Memecylon umbellatum burm. F*. Journal of applied Pharmaceutical science, 2011. **1**(1): p. 42.
44. Srinivasan, R., D. Natarajan, and M. Shivakumar, *In vitro evaluation of antioxidant, antiproliferative potentials of bioactive extract-cum-rutin compound Isolated from Memecylon edule leaves and its molecular docking study*. Journal of Biologically Active Products from Nature, 2016. **6**(1): p. 43-58.
45. Joshi, H., et al., *Evaluation of antipyretic potential of Memecylon umbellatum root extract*. Indian Journal of Natural Products, 2009. **25**(1): p. 13-16.
46. Asha, B., M. Krishnappa, and R. Kenchappa, *In vitro Anthelmintic Activity of Different Extracts of Memecylon umbellatum Burm*. Science, Technology and Arts Research Journal, 2015. **4**(4): p. 127-130.
47. Killedar, S. and H. More, *Analgesic and anti-Inflammatory studies of Memecylon umbellatum Burm roots in experimental animals*. Research Journal of Pharmacy and Technology, 2009. **2**(4): p. 858-861.
48. Joshi, H., et al., *Hepatoprotective activity of Memecylon umbellatum roots against acetaminophen induced hepatotoxicity in rats*. J Res Educ Indian Med, 2008. **14**(2): p. 49-54.
49. Amalraj, T. and S. Ignacimuthu, *Evaluation of the hypoglycaemic effect of Memecylon umbellatum in normal and alloxan diabetic mice*. Journal of ethnopharmacology, 1998. **62**(3): p. 247-250.
50. Puratchikody, A. and G. Nagalakshmi, *Wound healing activity of Memecylon umbellatum Burm*. Journal of plant sciences, 2007. **2**(2): p. 179-186.
51. Bharathi, T., K. Sampath Kumara, and H. Prakash, *Memecylon species: A review of traditional information and taxonomic description*. International Journal of Pharmacy and Pharmaceutical Sciences, 2016. **8**(6): p. 26-34.
52. Sivu, A.R. and M.K.R. Narayanan, *A new species of Memecylon (Melastomataceae) from the Western Ghats, India*. Phytotaxa, 2014. **162**(1): p. 44-50.
53. Reddy, K., C. Reddy, and V. Raju, *Memecylon jadhavii (Melastomataceae): A new species from Andhra Pradesh, India*. Journal of Economic and Taxonomic Botany, 2004. **28**(1): p. 165-166.
54. Ayyanar, M., K. Sankarasivaraman, and S. Ignacimuthu, *Traditional herbal medicines used for the treatment of diabetes among two major tribal groups in south Tamil Nadu, India*. Ethnobot Leaflets, 2008. **12**: p. 276-280.

55. Nature, I.U.f.C.o., I.S.S. Commission, and N.R.S.S. Commission, *IUCN Red List categories and criteria*2001: IUCN.
56. Ravishankar, T., *Rediscovery of Memecylon sisparenses Gamble (Melastomataceae) 110 years after Type collection* K. Ravikumar, R. Vijaya Sankar Plant Diversity.Human welfare and conservation, **2003**.p. 151-156.
57. Murugesan, M., V. Balasubramaniam, and S. Paulsamy, *Rediscovery of Memecylon sisparenses Gamble (Melastomataceae) and Swertia beddomei CB Clarke (Gentianaceae)*. Rheedea, 2007. **17**(1-2): p. 33-34.
58. Das, M.D., A. Pramanik, and D. Maity, *Lectotypification of Memecylon sisparenses (Memecylaceae)*. Rheedea. **24**(1): p. 21-22.
59. Sivu, A., et al., *Evaluation of phytochemical, antioxidant and antimicrobial activities of Memecylon L. species from Western Ghats*. Indian Journal of Natural Products and Resources, 2013. **4**(4): p. 363- 370
60. Murugan, T., J.A. Wins, and M. Murugan, *Antimicrobial activity and phytochemical constituents of leaf extracts of Cassia auriculata*. Indian journal of pharmaceutical sciences, 2013. **75**(1): p. 122.
61. Srinivasan, R., D. Natarajan, and M. Shivakumar, *Antimicrobial and GC-MS analysis of Memecylon edule leaf extracts*. Inter J Current Pharma Review Res, 2014. **5**(1): p. 1-13.
62. Organization, W.H., *Antimicrobial resistance: global report on surveillance*2014: World Health Organization.
63. Scalbert, A., et al., *Dietary polyphenols and the prevention of diseases*. Critical reviews in food science and nutrition, 2005. **45**(4): p. 287-306.
64. Brighente, I., et al., *Antioxidant activity and total phenolic content of some Brazilian species*. Pharmaceutical Biology, 2007. **45**(2): p. 156-161.
65. Ak, T. and İ. Gülçin, *Antioxidant and radical scavenging properties of curcumin*. Chemico-biological interactions, 2008. **174**(1): p. 27-37.
66. Harun, A., et al., *COMPARATIVE STUDY OF ANTIOXIDANT AND ANTIMICROBIAL ACTIVITY OF ROOT, STEM AND LEAVES OF LEEA INDICA SPECIES*. Malaysian Journal of Science, 2016. **35**(2): p. 241-250.
67. Kayalvizhi, K., L. Cathrine, and K.S. Banu, *Phytochemical and antibacterial studies on the leaf extracts of female Carica papaya. linn*. International Journal of PharmTech Research, 2015. **8**(7): p. 166-170.
68. James, O. and E.T. Friday, *Proximate and nutrient composition of Euphorbia hetrophylla: A medicinal plant from Anyigba, Nigeria*. Journal of Medicinal Plants Research, 2013. **4**(14): p. 1428-1431.
69. Kumar, H.K., et al., *In vitro antimicrobial activity and phytochemical screening of Aloe vera Linn*. International journal of current pharmaceutical research, 2012. **4**(3): p. 45-47.
70. Van den Dool, H. and P.D. Kratz, *A generalization of the retention index system including linear temperature programmed gas—liquid partition chromatography*. Journal of Chromatography A, 1963. **11**: p. 463-471.
71. Rashida, M.M.O., et al., *Antibacterial Activity of Polyaniline Coated Silver Nanoparticles Synthesized from Piper Betle Leaves Extract*. Iranian journal of pharmaceutical research: IJPR, 2016. **15**(2): p. 591.
72. Qadir, U., V. Paul, and P. Ganesh, *Preliminary phytochemical screening and in vitro antibacterial activity of Anamirta cocculus (Linn.) seeds*. Journal of King Saud University-Science, 2015. **27**(2): p. 97-104.

73. Balouiri, M., M. Sadiki, and S.K. Ibnsouda, *Methods for in vitro evaluating antimicrobial activity: A review*. Journal of Pharmaceutical Analysis, 2016. **6**(2): p. 71-79.
74. Gahlaut, A. and A.K. Chhillar, *Evaluation of antibacterial potential of plant extracts using resazurin based microtiter dilution assay*. International Journal of Pharmacy and Pharmaceutical Sciences, 2013. **5**(2): p. 372-376.
75. Nikolić, B., et al., *Screening of the antibacterial effect of Juniperus sibirica and Juniperus sabina essential oils in a microtitre plate-based MIC assay*. Botanica Serbica, 2016. **40**(1).
76. Duke, J.A. and S.M. Beckstrom-Sternberg, *Dr. Duke's phytochemical and ethnobotanical databases*. 1994.
77. Bharathi, T., H. Shankara, and H. Prakash, *Alpha Tocopherol-A New Report from Memecylon Species*. Indian journal of pharmaceutical sciences, 2017. **79**(5): p. 844-848.
78. Rumzhum, N.N., et al., *Evaluation of Antioxidant, Antino Potentialities of Methanolic Extract of Memecylon umbellatum*. Research Journal of Pharmacognosy and Phytochemistry, 2012. **4**(2): p. 84.
79. Killedar, S.G. and H.N. More, *Screening of antimicrobial potential and phytoconstituents for different extracts of Memecylon umbellatum Burm inflorescences*. Asian Journal of Pharmaceutical Research, 2011. **1**(4): p. 114-118.
80. Harkare, B.R., et al., *Phytochemical analysis and antibacterial activity of methanolic seed extract of Memecylon umbellatum burm*. IJPBS, 2013. **3**(2): p. 373-378.
81. Murugesan, S., R. Vijayakumar, and A. Panneerselvam, *Evaluation of Phytochemical Constituents from the Leaves of Memecylon umbellatum Burm. f.* Research Journal of Pharmaceutical, Biological and Chemical Sciences, 2011. **2**(4): p. 1145-1152.
82. Miller, R.P., et al., *Mechanisms of cisplatin nephrotoxicity*. Toxins, 2010. **2**(11): p. 2490-2518.
83. Shahid, F., Z. Farooqui, and F. Khan, *Cisplatin-induced gastrointestinal toxicity: An update on possible mechanisms and on available gastroprotective strategies*. European journal of pharmacology, 2018. **827**: p. 49-57.
84. Almutairi, M.M., et al., *Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model*. BMC complementary and alternative medicine, 2017. **17**(1): p. 472.
85. Çakır, D.Ü., Z. ALTUN, and N. OLGUN, *CYTOTOXIC AND MOLECULAR MECHANISMS IN OTOTOXICITY OF CISPLATIN*. Journal of Scientific Perspectives, 2018. **2**(2): p. 43-60.
86. Zenitani, M., et al., *Myeloprotective effects of C-type natriuretic peptide on cisplatin-induced bone marrow granulocytopenia in mice*. Cancer chemotherapy and pharmacology, 2017. **79**(2): p. 363-368.
87. Huang, Y.-C., et al., *Galangin ameliorates cisplatin-induced nephrotoxicity by attenuating oxidative stress, inflammation and cell death in mice through inhibition of ERK and NF-kappaB signaling*. Toxicology and applied pharmacology, 2017. **329**: p. 128-139.
88. Peres, L.A.B. and A.D.d. Cunha Júnior, *Acute nephrotoxicity of cisplatin: molecular mechanisms*. Jornal Brasileiro de Nefrologia, 2013. **35**(4): p. 332-340.
89. Ingale, K.G., P.A. Thakurdesai, and N.S. Vyawahare, *Protective effect of Hygrophila spinosa against cisplatin induced nephrotoxicity in rats*. Indian journal of pharmacology, 2013. **45**(3): p. 232.

90. Karadeniz, A., et al., *Royal jelly modulates oxidative stress and apoptosis in liver and kidneys of rats treated with cisplatin*. *Oxidative medicine and cellular longevity*, 2011. **2011**.
91. Ohkawa, H., N. Ohishi, and K. Yagi, *Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction*. *Analytical biochemistry*, 1979. **95**(2): p. 351-358.
92. Ellman, G.L., *Tissue sulfhydryl groups*. *Archives of biochemistry and biophysics*, 1959. **82**(1): p. 70-77.
93. Garratt, D.C., *The quantitative analysis of drugs* 2012: Springer Science & Business Media.
94. Aebi, H., *Catalase in vitro*. *Methods in enzymology*, 1984. **105**: p. 121-126.
95. Zimmermann, S.C., B. Duvall, and T. Tsukamoto, *Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase*. *Journal of medicinal chemistry*, 2018. DOI: 10.1021/acs.jmedchem.8b00327
96. McDermott, L.A., et al., *Design and evaluation of novel glutaminase inhibitors*. *Bioorganic & medicinal chemistry*, 2016. **24**(8): p. 1819-1839.
97. Huang, Q., et al., *Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism*. *Journal of Biological Chemistry*, 2018. **293**: p. 3535-3545.
98. Katt, W.P., M.J. Lukey, and R.A. Cerione, *A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis*. *Future medicinal chemistry*, 2017. **9**(2): p. 223-243.
99. Ramachandran, S., et al., *Structural basis for exploring the allosteric inhibition of human kidney type glutaminase*. *Oncotarget*, 2016. **7**(36): p. 57943.
100. Morris, G.M., et al., *AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility*. *Journal of computational chemistry*, 2009. **30**(16): p. 2785-2791.
101. Johansson, M.U., et al., *Defining and searching for structural motifs using DeepView/Swiss-PdbViewer*. *BMC bioinformatics*, 2012. **13**(1): p. 173.
102. Naqshbandi, A., et al., *Studies on the protective effect of dietary fish oil on cisplatin induced nephrotoxicity in rats*. *Food and Chemical Toxicology*, 2012. **50**(2): p. 265-273.
103. Arcamone, F., et al., *Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius*. *Biotechnology and bioengineering*, 1969. **11**(6): p. 1101-1110.
104. Tacar, O., P. Sriamornsak, and C.R. Dass, *Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems*. *Journal of Pharmacy and Pharmacology*, 2013. **65**(2): p. 157-170.
105. Jungsuwadee, P., *Doxorubicin-induced cardiomyopathy: an update beyond oxidative stress and myocardial cell death*. *Cardiovascular Regenerative Medicine*, 2016. **3**: p. 1127.
106. Octavia, Y., et al., *Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies*. *Journal of molecular and cellular cardiology*, 2012. **52**(6): p. 1213-1225.
107. Gammella, E., S. Recalcati, and G. Cairo, *Dual role of ROS as signal and stress agents: iron tips the balance in favor of toxic effects*. *Oxidative medicine and cellular longevity*, 2016. **2016** Article ID 8629024, 9 pages.
108. Chatterjee, K., et al., *Doxorubicin cardiomyopathy*. *Cardiology*, 2010. **115**(2): p. 155-162.

109. Hull, T.D., et al., *Heme oxygenase-1 regulates mitochondrial quality control in the heart*. JCI insight, 2016. **1**(2).
110. Barry, E., et al., *Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management*. Expert opinion on pharmacotherapy, 2007. **8**(8): p. 1039-1058.
111. Spudich, J.A., *Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases*. Biophysical journal, 2014. **106**(6): p. 1236-1249.
112. Kovács, M., et al., *Analysis of nucleotide binding to Dictyostelium myosin II motor domains containing a single tryptophan near the active site*. Journal of Biological Chemistry, 2002. **277**: p. 28459-28467.
113. Sugamura, K. and J.F. Keaney, *Reactive oxygen species in cardiovascular disease*. Free Radical Biology and Medicine, 2011. **51**(5): p. 978-992.
114. Liu, X., et al., *Pifithrin- $\alpha$  protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice*. American Journal of Physiology-Heart and Circulatory Physiology, 2004. **286**(3): p. H933-H939.
115. Angsutararux, P., S. Luanpitpong, and S. Issaragrisil, *Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress*. Oxidative medicine and cellular longevity, 2015. **2015** Article ID 795602, 13 pages.
116. Yao, H., et al., *Triple-negative breast cancer: is there a treatment on the horizon?* Oncotarget, 2017. **8**(1): p. 1913.
117. Kim, J.Y., et al., *Annona muricata Leaf Extract Triggered Intrinsic Apoptotic Pathway to Attenuate Cancerous Features of Triple Negative Breast Cancer MDA-MB-231 Cells*. Evidence-Based Complementary and Alternative Medicine, 2018. **2018** Article ID 7972916, 10 pages.
118. Ansari, F., *AGE AT MENARCHE AND INCIDENCE OF BREAST CANCER IN DIFFERENT STATES OF INDIA: A SITUATIONAL ANALYSIS*. INDIAN JOURNAL OF APPLIED RESEARCH, 2018. **8**(3): p. 2673.
119. Manikandarajan, P., et al., *ISOLATION, CHARACTERIZATION, DOCKING AND ANTI-CANCER ACTIVITY OF QUERCETIN FROM LEAVES OF EUPHORBIA HETEROPHYLLA LINN*. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2018. **9**(1): p. 197-202.
120. Puttaswamy, R., et al., *Anti-Cancer Activity of Memecylon Umbellatum Leaf Extract*. World Journal of Pharmacy and Pharmaceutical Sciences, 2013. **2**(6): p. 5997-6000.
121. Chaudhary, S., et al., *Screening of Anticancer Activity of Selected Medicinal Plants Indigenous to Western Ghats: Argyreia nervosa, Memecylon malabaricum and Memecylon umbellatum*. Advanced Science Letters, 2017. **23**(3): p. 1781-1784.

## APPENDIX A

### Plant Authentication certificate

SRI VENKATESWARA UNIVERSITY  
TIRUPATI-517 502, A.P., INDIA

Dr. K. MADHAVA CHETTY

M.Sc., M.Ed., M.Phil., Ph.D., PG DPD  
Plant Taxonomist (IAAT: 357)  
Assistant Professor  
Department of Botany



Mobile: +91-9490486654  
Phone: +91-877-2233685 (R)

Email: madhavachetty@gmail.com

Date: 10. 11. 2015

### AUTHENTICATION CERTIFICATE

I hereby certify that the following plant species for pharmacognostical / pharmaceutical / pharmacological / phytochemical investigation research work is identified and their botanical name and family name is given .

| Botanical Name                       | Voucher number | Family        |
|--------------------------------------|----------------|---------------|
| <i>Memecylon sisparens</i><br>Gamble | 984            | Melastomaceae |

Authenticated by

*K. Madhava Chetty*

(K. MADHAVA CHETTY)

**DR. K. MADHAVA CHETTY**

M.Sc., M.Ed., M.Phil., Ph.D., PG DPD  
ASSISTANT PROFESSOR  
DEPARTMENT OF BOTANY  
SRI VENKATESWARA UNIVERSITY  
TIRUPATI-517 502, A.P. India